BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20403998)

  • 1. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.
    Bertagnolli MM; Hsu M; Hawk ET; Eagle CJ; Zauber AG;
    Cancer Prev Res (Phila); 2010 May; 3(5):588-96. PubMed ID: 20403998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib for the prevention of sporadic colorectal adenomas.
    Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
    N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
    Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Breazna A; Kim K; Tang J; Rosenstein RB; Umar A; Bagheri D; Collins NT; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Hawk ET;
    Cancer Prev Res (Phila); 2009 Apr; 2(4):310-21. PubMed ID: 19336730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
    Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
    Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
    Thompson P; Roe DJ; Fales L; Buckmeier J; Wang F; Hamilton SR; Bhattacharyya A; Green S; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Martinez ME; Jacobs E; Ashbeck EL; Alberts DS; Lance P
    Cancer Prev Res (Phila); 2012 Dec; 5(12):1381-93. PubMed ID: 23060037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
    Chan AT; Sima CS; Zauber AG; Ridker PM; Hawk ET; Bertagnolli MM
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1172-80. PubMed ID: 21816845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
    Wang J; Carvajal-Carmona LG; Chu JH; Zauber AG; ; Kubo M; Matsuda K; Dunlop M; Houlston RS; Sieber O; Lipton L; Gibbs P; Martin NG; Montgomery GW; Young J; Baird PN; Ratain MJ; Nakamura Y; Weiss ST; Tomlinson I; Bertagnolli MM
    Clin Cancer Res; 2013 Dec; 19(23):6430-7. PubMed ID: 24084763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
    Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
    Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
    N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
    Chan AT; Zauber AG; Hsu M; Breazna A; Hunter DJ; Rosenstein RB; Eagle CJ; Hawk ET; Bertagnolli MM
    Gastroenterology; 2009 Jun; 136(7):2127-2136.e1. PubMed ID: 19233181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
    Chan AT; Hsu M; Zauber AG; Hawk ET; Bertagnolli MM
    Cancer Prev Res (Phila); 2012 Jan; 5(1):61-72. PubMed ID: 22030088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
    Thompson PA; Ashbeck EL; Roe DJ; Fales L; Buckmeier J; Wang F; Bhattacharyya A; Hsu CH; Chow SH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Hamilton SR; Jacobs ET; Martinez EM; Alberts DS; Lance P
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27530656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
    Arguedas MR; Heudebert GR; Wilcox CM
    Aliment Pharmacol Ther; 2001 May; 15(5):631-8. PubMed ID: 11328256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
    Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
    Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin use and the risk of colorectal adenoma: A meta-analysis.
    Jung YS; Park CH; Eun CS; Park DI; Han DS
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1823-1830. PubMed ID: 27043957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
    Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
    Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
    [No Abstract]   [Full Text] [Related]  

  • 19. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes.
    Thompson PA; Ashbeck EL; Roe DJ; Fales L; Buckmeier J; Wang F; Bhattacharyya A; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Hamilton SR; Jacobs ET; Martinez ME; Alberts DS; Lance P
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27530657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.